BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17893499)

  • 21. Oesophagectomy for tumours and dysplasia of the oesophagus and gastro-oesophageal junction.
    Epari K; Cade R
    ANZ J Surg; 2009 Apr; 79(4):251-7. PubMed ID: 19432710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.
    Tulchinsky H; Shmueli E; Figer A; Klausner JM; Rabau M
    Ann Surg Oncol; 2008 Oct; 15(10):2661-7. PubMed ID: 18389322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
    Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
    J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study.
    Hsu FM; Lin CC; Lee JM; Chang YL; Hsu CH; Tsai YC; Lee YC; Cheng JC
    J Surg Oncol; 2008 Jul; 98(1):34-41. PubMed ID: 18449912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
    Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
    Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
    Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer.
    Ruol A; Portale G; Castoro C; Merigliano S; Cagol M; Cavallin F; Chiarion Sileni V; Corti L; Rampado S; Costantini M; Ancona E
    Ann Surg Oncol; 2007 Nov; 14(11):3243-50. PubMed ID: 17713823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
    Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
    Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative and adjuvant therapies for upper gastrointestinal cancers.
    Varadhachary G; Ajani JA
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):719-25. PubMed ID: 16111471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.
    Lim SB; Choi HS; Jeong SY; Kim DY; Jung KH; Hong YS; Chang HJ; Park JG
    Ann Surg; 2008 Aug; 248(2):243-51. PubMed ID: 18650634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction therapy does not increase surgical morbidity after esophagectomy for cancer.
    Lin FC; Durkin AE; Ferguson MK
    Ann Thorac Surg; 2004 Nov; 78(5):1783-9. PubMed ID: 15511475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography.
    Lordick F
    Recent Results Cancer Res; 2012; 196():201-11. PubMed ID: 23129376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution.
    Ruol A; Castoro C; Portale G; Cavallin F; Sileni VC; Cagol M; Alfieri R; Corti L; Boso C; Zaninotto G; Peracchia A; Ancona E
    Arch Surg; 2009 Mar; 144(3):247-54; discussion 254. PubMed ID: 19289664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
    Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of neoadjuvant therapy for esophageal adenocarcinoma.
    Ku GY; Ilson DH
    Surg Oncol Clin N Am; 2009 Jul; 18(3):533-46. PubMed ID: 19500742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
    Milman S; Kim AW; Warren WH; Liptay MJ; Miller C; Basu S; Faber LP
    Ann Thorac Surg; 2009 Sep; 88(3):945-50; discussion 950-1. PubMed ID: 19699925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome after esophagectomy for cancer of the esophagus and GEJ in patients aged over 75 years.
    Internullo E; Moons J; Nafteux P; Coosemans W; Decker G; De Leyn P; Van Raemdonck D; Lerut T
    Eur J Cardiothorac Surg; 2008 Jun; 33(6):1096-104. PubMed ID: 18407509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
    Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
    Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
    Ott K; Weber WA; Lordick F; Becker K; Busch R; Herrmann K; Wieder H; Fink U; Schwaiger M; Siewert JR
    J Clin Oncol; 2006 Oct; 24(29):4692-8. PubMed ID: 16966684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.